Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285855 · ClinicalTrials.gov registry record · Phase 2
Metformin in Non Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02285855: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02285855 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02285855, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving metformin in combination with radiation therapy is more effective than radiation therapy alone. In this study, participants will receive either metformin or a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. This is an investigational study. Metformin is FDA approved for the treatment of diabetes. Its use in this study to be given with radiation therapy to treat lung cancer is investigational. The study doctor can explain how the study drug is designed to work. Up to 70 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- OTHER Placebo
- DRUG Metformin
- RADIATION Stereotactic body Radiotherapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-02-20 |
| Est. Completion | 2019-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285855
The ClinicalTrials.gov registry entry for NCT02285855 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02285855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285855 about?
NCT02285855 is a clinical study titled "Metformin in Non Small Cell Lung Cancer (NSCLC)". The goal of this clinical research study is to learn if giving metformin in combination with radiation therapy is more effective than radiation therapy alone. In this study, participants will receive either metformin or a placebo. A placebo is not a drug. It looks like the study drug but is not desi...
What is the current status of trial NCT02285855?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2015-02-20. Estimated completion is 2019-01-05.
What interventions are being tested in trial NCT02285855?
The interventions under investigation include: Placebo (OTHER), Metformin (DRUG), Stereotactic body Radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT02285855?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.